Pharmafile Logo
Pharmafocus logo
Advanced Search

Trulicity

Showing 4 posts of 4 posts found.

lilly_entrance_web

Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

February 24, 2020
Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …

News
lilly_building_with_american_flag_web

Eli Lilly’s heart drug underwhelms with REWIND trial

June 11, 2019
Manufacturing and Production Eli Lilly, Trulicity, pharma

Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according …

News
lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …

News
lilly_entrance_web

Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2

June 25, 2018
Research and Development, Sales and Marketing Eli Lilly, Trulicity, diabetes, pharma

Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024